One of the most studied probiotics in the world
BioGaia’s probiotic products with Lactobacillus reuteri are among the most scientifically well-documented probiotics in the world with regard to both efficacy and safety. To date the efficacy and safety of BioGaia’s different strains of L. reuteri have been documented in 203 clinical studies in 17,200 people of all ages.
Lactobacillus reuteri has shown result in 105 clinical studies in children, from newborns up to 18 years old, and 98 studies in adults. Probiotic strains that have been used in clinical trials are BioGaia Protectis (DSM 17938), BioGaia Gastrus (ATCC PTA 6475) and BioGaia Prodentis (ATCC PTA 52899. Results have been published in 180 papers in scientific journals (February 2019).Find our products in your country
Safe for all ages
Safety has been proven in preterm babies, infants, children, healthy adults and immune compromised adults. No serious adverse effects have been observed up to the maximum tested dosage of 10 billion CFU per day, meaning 1000 times the recommended daily dose.
Lactobacillus reuteri is considered safe as it fulfills the following criteria:
- Human origin
- Named and classified according to correct taxonomy
- Manufactured under controlled conditions to eliminate contamination
- Safety is evaluated and documented on target population
- Harbors no toxins or transferrable antibiotic resistance genes
Dosage and colonization
Based on clinical data, 100 million CFU per day has been chosen as a safe and efficient dose of Lactobacillus reuteri Protectis for children and adults. The recommended dosage of probiotic bacteria depends on which strain or strains the product contains. For some probiotic strains, a relatively low amount of bacteria is needed, while other strains require a larger amount.
The epithelial lining covers our gastrointestinal tract and works like a skin on the inside of our bodies. The main task of our ”inner skin” is to differentiate between what should be absorbed and what should not be let into our bodies. Biopsies have shown that Lactobacillus reuteri is temporarily binding to our epithelial lining. However, since the cells in our epithelial lining is replaced every fourth day, the majority of L. reuteri cells are also washed away within a week or so. Since L. reuteri colonization is transient, every day intake is recommended to ensure adequate and stable levels of L. reuteri in the gastrointestinal tract. Colonization of L. reuteri Protectis has been proven throughout the entire human gastrointestinal tract using biopsies technique.Read more about Gatekeepers in the gut
The origin of Lactobacillus reuteri
The first strain of Lactobacillus reuteri (L. reuteri) for human use, L. reuteri DSM 17938, was isolated in 1990 from the breast milk of a Peruvian mother living in the Andes. The commercial name is L. reuteri Protectis. Other human strains from BioGaia are L. reuteri ATCC PTA 5289 and ATCC PTA 6475. L. reuteri ATCC PTA 5289 used in oral health products was isolated from the oral cavity of a Japanese woman with remarkably good dental status and L. reuteri ATCC PTA 6475 was isolated from breast milk in Finland.
Bacteria of human origin
All our commercial strains are of human origin, naturally colonize humans, and are therefore more likely to actually have a positive effect on human health. Even an indigenous bacterium like BioGaia’s L. reuteri Protectis should be taken on a regular basis, to reach high enough levels to achieve proper colonization and have a good effect. L. reuteri has been found in:
- Breast milk
- The vagina
- The mouth
- The stomach
- The small intestine
- The large intestine
Lactobacillus reuteri grounded in evolution
Research has shown that Lactobacillus reuteri is a species of bacteria that has developed a mutualistic relationship with its specific host over millions of years. In other words, throughout evolution certain strains of Lactobacillus reuteri have made their home in the specific environment that is found in the human gut. In some of us they still reside there today, while most others have insufficient levels.
The researcher Ivan Casas was fascinated by what he called the circle of life, how essential bacteria are transferred from parent to offspring and where the unique Lactobacillus reuteri was one bacteria that the mother should pass on to her child. Read more
BioGaia's products with Lactobacillus reuteri are sold through around 80 local distribution partners in 100 countries around the world.
BioGaia is an innovative Swedish health care company and a world leader in probiotics.
Probiotics grounded in evolution Driven by science
To date, 203 clinical studies using BioGaia’s human strains of L. reuteri have been performed on 17,200 individuals of all ages (February 2019).